Association of functional gene variants in the regulatory regions of COX-2 gene (PTGS2) with nonmelanoma skin cancer after organ transplantation

British Journal of Dermatology

Volumn 157, Issue 1, 2007, Pages 49-57

  Gomez Lira, M ^a   Mazzola, S ^a   Tessari, G ^a   Malerba, G ^a   Ortombina, M ^a   Naldi, L ^b   Remuzzi, G ^c   Boschiero, L ^a   Forni, A ^a   Rugiu, C ^a   Piaserico, S ^d   Girolomoni, G ^a   Turco, A ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b Centro Studi Gruppo Italiano di Studi Epidemiologici in Dermatologia   (Italy)

^c OSPEDALI RIUNITI   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

Author keywords

COX 2 gene; Nonmelanoma skin cancer; Polymorphisms; PTGS2; Transplantation

Indexed keywords

AZATHIOPRINE; CYCLOOXYGENASE 2; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ADULT; AGED; ALLELE; ARTICLE; BASAL CELL CARCINOMA; BOWEN DISEASE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DNA FLANKING REGION; FEMALE; FISHER EXACT TEST; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; GRAFT RECIPIENT; GRAFT REJECTION; HAPLOTYPE; HEART TRANSPLANTATION; HETERODUPLEX ANALYSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KERATOACANTHOMA; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MELANOMA; ORGAN TRANSPLANTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; REGULATOR GENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SQUAMOUS CELL CARCINOMA;

ADULT; CYCLOOXYGENASE 2; FEMALE; GENE FREQUENCY; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; ORGAN TRANSPLANTATION; POLYMORPHISM, GENETIC; REGULATORY SEQUENCES, NUCLEIC ACID; RISK FACTORS; SKIN NEOPLASMS;

EID: 34250686952     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.07921.x     Document Type: Article

References (57)

1. Moloney FJ, Comber H, O'Lorcain P et al. A population based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol 2006 154 : 498 504.
2. Liddington M, Richardson AJ, Higgins RM et al. Skin cancer in renal transplant recipients. Br J Surg 1998 76 : 1002 5.
3. Glover MT, Niranjan N, Kwan JT, Leigh IM. Non-melanoma skin cancer in renal transplant recipients: the extent of the problem and a strategy for management. Br J Plast Surg 1994 47 : 86 9.
4. Martinez JC, Otley CC, Stasko T et al. Transplant skin cancer collaborative. Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study. Arch Dermatol 2003 139 : 301 6.
5. Kovach BT, Sams HH, Stasko T. Systemic strategies for chemoprevention of skin cancers in transplant patients. Clin Transplant 2005 19 : 726 34.
6. Hall EJ, Astor M, Bedford J et al. Basic radiobiology. Am J Clin Oncol 1988 11 : 220 52.
7. Black HS, deGruijl FR, Forbes PD et al. Photocarcinogenesis: an overview. J Photochem Photobiol B 1997 40 : 29 47.
8. de Gruijl FR, van Kranen HJ, Mullenders LH. UV induced DNA damage, repair, mutations and oncogenic pathways in skin cancer. J Photochem Photobiol B 2001 63 : 19 27.
9. Griffiths H, Mistry P, Herbert K, Lunec J. Molecular and cellular effects of ultraviolet light induced genotoxicity. Crit Rev Clin Lab Sci 1998 35 : 189 237.
10. Larsson P, Andersson E, Johansson U et al. Ultraviolet A and B affect human melanocytes and keratinocytes differently. A study of oxidative alterations and apoptosis. Exp Dermatol 2005 14 : 117 23.
11. Aubin F, Humbey O, Guerrini JS et al. Non melanoma skin cancers and human papillomavirus. Ann Dermatol Venereol 2003 130 : 1131 8.
12. Bouwes Bavinck JN, Feltkamp M, Struijk L, ter Schegget J. Human papillomavirus infection and skin cancer risk in organ transplant recipients. J Invest Dermatol Symp Proc 2001 6 : 207 11.
13. Madan V, Hoban P, Strange RC, Fryer A et al. Genetics and risk factors for basal cell carcinoma. Br J Dermatol 2006 154 (Suppl. 1 5 7.
14. Tilli CM, van Steensel MA, Krekels GA et al. Molecular aetiology and pathogenesis of basal cell carcinoma. Br J Dermatol 2005 152 : 1108 24.
15. Dang C, Koehler A, Forschner T et al. E6/E7 expression of human papillomavirus types in cutaneous squamous cell dysplasia and carcinoma in immunosuppressed organ transplant recipients. Br J Dermatol 2006 155 : 129 36.
16. Vanderveen EE, Grekin RC, Swanson NA, Kragballe K. Arachidonic acid metabolites in cutaneous carcinomas. Evidence suggesting that elevated levels of prostaglandins in basal cell carcinomas are associated with an aggressive growth pattern. Arch Dermatol 1986 122 : 407 12.
17. Kruza LL, Pentland AP. Mechanisms of UV induced inflammation. J Invest Dermatol 1993 100 : 355 415.
18. Grewe M, Trefzer U, Ballhorn A et al. Analysis of the mechanism of ultraviolet (UV) B radiation induced prostaglandin E2 synthesis by human epidermoid carcinoma cells. J Invest Dermatol 1993 101 : 528 31.
19. Vane JR, Mitchel JA, Appleton I et al. Inducible isoform of cyclooxygenase and nitric oxide synthase in inflammation. Proc Natl Acad Sci USA 1994 91 : 2046 50.
20. Chandrasekharan NV, Simmons DL. The cyclooxygenases. Genome Biol 2004 5 : 241.
21. Buckman SY, Gresham A, Hale P et al. COX 2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998 19 : 723 9.
22. Kim KH, Park EJ, Seo Y et al. Immunohistochemical study of cyclooxygenase 2 and p53 expression in skin tumors. J Dermatol 2006 33 : 319 25.
23. Asgari M, White E, Chren MM. Nonsteroidal anti inflammatory drug use in the prevention and treatment of squamous cell carcinoma. Dermatol Surg 2004 30 : 1335 42.
24. Chun KS, Surh YJ. Signal transduction pathway regulating cyclooxygenase 2 expression: potential molecular targets for chemoprevention. Biochem Pharmacol 2004 68 : 1089 110.
25. Kosaka T, Miyata A, Ihara H et al. Characterization of the human gene (PTGS2) encoding prostaglandin endoperoxide synthase 2. Eur J Biochem 1994 221 : 889 97.
26. Cok SJ, Morrison AR. The 3′ untranslated region of murine cyclooxygenase 2 contains multiple regulatory elements that alter message stability and translational efficiency. J Biol Chem 2001 276 : 23179 85.
27. Papafili A, Hill MR, Brull D et al. Common promoter variant in cyclooxygenase 2 represses gene expression: evidence of role in acute phase inflammatory response. Arterioscler Thromb Vasc Biol 2002 22 : 1631 6.
28. Zhang X, Miao X, Tan W et al. Identification of functional genetic variants in cyclooxygenase 2 and their association with risk of esophageal cancer. Gastroenterology 2005 129 : 565 76.
29. Park JM, Choi JE, Chae MH et al. Relationship between cyclooxygenase 8473T→C polymorphism and the risk of lung cancer: a case-control study. BMC Cancer 2006 6 : 70.
30. Langsenlehner U, Yazdani Biuki B, Eder T et al. The cyclooxygenase 2 (PTGS2) 8473T→C polymorphism is associated with breast cancer risk. Clin Cancer Res 2006 12 : 1392 4.
31. Ali IU, Luke BT, Dean M, Greenwald P. Allelic variants in regulatory regions of cyclooxygenase 2: association with advanced colorectal adenoma. Br J Cancer 2005 93 : 953 9.
32. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004 351 : 2715 29.
33. Boukamp P. Non melanoma skin cancer: what drives tumor development and progession? Carcinogenesis 2005 26 : 1657 67.
34. Lee JL, Kim A, Kopelovich L et al. Differential expression of E prostanoid receptors in murine and human non melanoma skin cancer. J Invest Dermatol 2005 12 : 818 25.
35. Mithoefer AB, Supran S, Freeman RB. Risk factors associated with the development of skin cancer after liver transplantation. Liver Transpl 2002 8 : 939 44.
36. Herrero JI, Lorenzo M, Quiroga J et al. De novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival. Liver Transpl 2005 11 : 89 97.
37. Rohde K, Fuerst R. Haplotyping and estimation of haplotype frequencies for closely linked biallelic multilocus genetic phenotypes including nuclear family information. Hum Mutat 2001 17 : 289 95.
38. Sheng H, Shao J, Washington MK, DuBois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001 276 : 18075 81.
39. Tsujii M, Kawano S, Tsuji S et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998 93 : 705 16.
40. Nijsten T, Colpaert CG, Vermeulen PB et al. Cyclooxygenase 2 expression and angiogenesis in squamous cell carcinoma of the skin and its precursors: a paired immunohistochemical study of 35 cases. Br J Dermatol 2004 151 : 837 45.
41. O'Grady A, O'Kelly P, Murphy GM et al. COX 2 expression correlates with microvessel density in non melanoma skin cancer from renal transplant recipients and immunocompetent individuals. Hum Pathol 2004 35 : 1549 55.
42. Tjiu JW, Liao YH, Lin SJ et al. Cyclooxygenase 2 overexpression in human basal cell carcinoma cell line increases antiapoptosis, angiogenesis, and tumorigenesis. J Invest Dermatol 2006 126 : 1143 51.
43. Dohadwala M, Luo J, Zhu L et al. Non small cell lung cancer cyclooxygenase 2 dependent invasion is mediated by CD44. J Biol Chem 2001 276 : 20809 12.
44. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995 83 : 493 501.
45. Sheng H, Shao J, Morrow JD et al. Modulation of apoptosis and Bcl 2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998 58 : 362 6.
46. Cipollone F, Toniato E, Martinoti S et al. A polymorphism in the cyclooxygenese 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA 2004 291 : 2221 40.
47. Shao J, Sheng H, Inoue H et al. Regulation of constitutive cyclooxygenase 2 expression in colon carcinoma cells. J Biol Chem 2000 275 : 33951 6.
48. Inoue H, Yokoyama C, Hara S et al. Transcriptional regulation of human prostaglandin endoperoxide synthase 2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin 6 expression site and cAMP response element. J Biol Chem 1995 270 : 24965 71.
49. Skim J, Karin M. The control of mRNA stability in response to extracellular stimuli. Mol Cell 2002 14 : 323 31.
50. Kim Y, Fischer SM. Transcriptional regulation of cyclooxygenase 2 in mouse skin carcinoma cells. J Biol Chem 1998 273 : 27686 94.
51. Dixon DA, Kaplan CD, McIntyre TM et al. Post transcriptional control of cyclooxygenase 2 gene expression. J Biol Chem 2000 275 : 11750 7.
52. Liu F, Pan K, Zhang X et al. Genetic variants in cyclooxygenase 2: expression and risk of gastric cancer and its precursors in a Chinese population. Gastroentorology 2006 130 : 1975 84.
53. Zhang XM, Miao XP, Tan W et al. Genetic polymorphisms in the promoter region of cyclooxygenase 2 and their association with risk of gastric cancer. Chung-Kuo i Hsueh Ko Hsueh Yuan Hsueh Pao Acta Academiae Medicinae Sinicae 2006 28 : 119 23.
54. Szczeklik W, Sanak M, Szczeklik A. Functional effects and gender association of COX 2 gene polymorphism G765C in bronchial asthma. J Allergy Clin Immunol 2004 114 : 248 53.
55. Jee SH, Chu CY, Chiu HC et al. Interleukin-6 induced basic fibroblast growth factor-dependent angiogenesis in basal cell carcinoma cell line via JAK/STAT3 and PI3 kinase/Akt pathways. J Invest Dermatol 2004 123 : 1169 75.
56. Takeda T, Kurachi H, Yamamoto T et al. Crosstalk between the interleukin-6 (IL-6)-JAK-STAT and the glucocorticoid-nuclear receptor pathway: synergistic activation of IL-6 response element by IL-6 and glucocorticoid. J Endocrinol 1998 159 : 323 30.
57. Karagas MR, Cushing GL Jr., Greenberg ER et al. Non melanoma skin cancers and glucocorticoid therapy. Br J Cancer 2001 85 : 683 6.